219 completed, 96 unknown, 56 terminated, 33 recruiting. 265 Phase 2, 116 Phase 3, 66 Phase 1, 8 Not applicable, 8 Phase 4.
Follow Vinorelbine: new trials by email Literature Review of Vinorelbine trials Research Report on Vinorelbine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma VT3989, gemcitabine, Vinorelbine - Pleural Mesothelioma, Mesothelioma | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | 350 | 2026-12-01 | 2026-09-17 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 90 | 2026-10-31 | 2026-09-17 |
| Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease Paclitaxel, Bevacizumab, Carboplatin - Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD) | Phase 2 | Not yet recruiting | Intergroupe Francophone de Cancerologie Thoracique | 108 | 2026-09-15 | 2026-08-11 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer SYS6010, Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) - Recurrent or Metastatic Breast Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-04-01 | 2026-02-12 |
| A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection - Triple Negative Breast Cancer | Phase 3 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 364 | 2026-03-17 | 2026-04-16 |
| YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer YL202, Eribulin, Capecitabine - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 376 | 2026-03-17 | 2026-05-26 |
| The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis Trastuzumab Rezetecan, Chemotherapy of Physician's Choice - HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 184 | 2026-03-01 | 2026-10-15 |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) - Metastatic Breast Cancer in the Liver | Phase 2 | Recruiting | Delcath Systems Inc. | 90 | 2026-01-29 | 2026-10-19 |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated Tepotinib, Pemetrexed (Alimta), Vinorelbine - Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 133 | 2025-12-09 | 2025-12-17 |
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer MaaT033 capsule, Cemiplimab, Cisplatin - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 162 | 2025-11-17 | 2026-04-03 |
| Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer Gemcitabine, Vinorelbine, Eribulin, or Utidelone - Breast Neoplasms | Phase 3 | Recruiting | Sun Yat-sen University | 192 | 2025-09-15 | 2025-12-11 |
| Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients Atezolizumab in combination with Cyclophosphamide and Vinorelbine - Triple Negative Breast Cancer | Phase 2 | Recruiting | European Institute of Oncology | 45 | 2025-03-06 | 2026-01-05 |
| Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer. Capecitabine, Vinorelbine, Etoposide - Breast Cancer | Not applicable | Unknown | QIAO LI | 40 | 2025-03-01 | 2025-03-04 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients Docetaxel, Paclitaxel, Gemcitabine - NSCLC | Not applicable | Recruiting | University of Illinois at Chicago | 29 | 2024-12-16 | 2026-01-20 |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Surgical Procedure, Cisplatin, Carboplatin - Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 37 | 2024-12-11 | 2026-09-02 |
Showing 20 of 448. Sign in to see all of them.
Breast Neoplasms (168) · Carcinoma, Non-Small-Cell Lung (111) · Lung Neoplasms (54) · Hodgkin Disease (22) · Neoplasm Metastasis (17) · Recurrence (16) · Lymphoma (15) · Neoplasms (14) · Triple Negative Breast Neoplasms (14) · Adenocarcinoma of Lung (10) · Prostatic Neoplasms (10) · Rhabdomyosarcoma (9) · Sarcoma (9) · Lymphoma, Non-Hodgkin (8) · Uterine Cervical Neoplasms (8)
Fudan University (12) · Sun Yat-sen University (11) · National Cancer Institute (NCI) (10) · Hellenic Oncology Research Group (9) · Children's Oncology Group (7) · Dana-Farber Cancer Institute (7) · Hoffmann-La Roche (7) · Memorial Sloan Kettering Cancer Center (7) · University of Washington (7) · Alliance for Clinical Trials in Oncology (6) · Eli Lilly and Company (6) · SWOG Cancer Research Network (6) · AstraZeneca (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · GlaxoSmithKline (5)
United States (160) · China (96) · France (63) · Italy (57) · Germany (49) · Spain (45) · United Kingdom (42) · Canada (38) · Belgium (31) · Australia (29) · South Korea (27) · Greece (22) · Poland (21) · Netherlands (20) · Switzerland (20)
Armando Santoro, MD (4) · Binghe Xu (3) · Cesare Gridelli, M.D. (3) · Dimitris Mavrudis, MD (3) · Francesco Perrone, M.D., Ph.D. (3) · Jian Zhang (3) · Jiong Wu (3)
PMID 34037241, PMID 31430226, PMID 33093337, PMID 37505794, PMID 40421698, PMID 40657894, PMID 41698326, PMID 10080612, PMID 10655437, PMID 11937316, PMID 12065558, PMID 12142053, PMID 12177103, PMID 12434281, PMID 12618501, PMID 12837810, PMID 1310103, PMID 14506149, PMID 14736927, PMID 15073859, PMID 15165094, PMID 15246197, PMID 15297403, PMID 15310778, PMID 15550580, PMID 15713522, PMID 15972865, PMID 16011702, PMID 16078267, PMID 16157935, PMID 16204011, PMID 16226617, PMID 16235286, PMID 16265674, PMID 1648142, PMID 16510333, PMID 16520332, PMID 16598416, PMID 16645718, PMID 16957145, PMID 17075123, PMID 17141357, PMID 17289895, PMID 17329192, PMID 17374151, PMID 17409914, PMID 17426059, PMID 17442999, PMID 17488518, PMID 17544337
2016 (7), 2015 (6), 2017 (5), 2023 (5), U10CA032102 (5), U10CA098543 (5), 2018 (4), 2005 (3), 2014 (3), P30CA043703 (3), U10CA180886 (3), 2008 (2), 2009 (2), P30CA033572 (2), P50CA058223 (2)